PRICEFX
15.5.2019 11:02:11 CEST | Business Wire | Press release
Pricefx , the global leader in cloud pricing software, today announced on stage at its user conference Accelerate19 that subscribers of the company’s core SaaS product offerings will now receive full access to the entire platform feature set for no additional cost. This is possible now that Pricefx has completed its evolution to a platform provider and unified its integration and connectivity capabilities. Pricefx’s powerful enterprise-grade technology platform provides simple point-and-click configuration for back-end, front-end, primary and third-party intellectual property (IP) enablement.
By including the platform with core product subscriptions, Pricefx will further lower the total cost of ownership for its customers. Additionally, the platform’s simple access to a broad range of pricing IP and ready-made capabilities will accelerate customer time-to-value on the Pricefx investment.
“The evolution from discrete solutions to a full-featured platform creates a new benchmark for best-in-class cloud pricing,” said Gabriel Smith, chief evangelist at Pricefx. “We are delivering powerful and innovative new features that create a more connected, integrated and modular cloud-native platform -- and at no additional charge to customers. Organizations can now harness unprecedented power of the full Pricefx product suite delivered through an enterprise-scale platform that manages data, multi-system connectivity, and more, with the same fast, flexible and friendly SaaS approach the industry has come to expect from Pricefx.”
Previously, Pricefx offered IntegrationManager as separate product which connected Pricefx SaaS products with back-end data and services such as ERP and PLM systems. Pricefx also continued to build front-end systems integrations with leading providers and helped its partners develop focused and pricing-specific IP. Today, these capabilities have been unified inside a single platform free to customers of the company’s core SaaS products and to partners for the development, addition and distribution of its own IP.
The Pricefx platform will continue to provide and support all of the back-end connectivity and capabilities of IntegrationManager and will continue enabling connectivity with leading CRM systems and across the Pricefx suite of products. Now customers can more easily integrate Pricefx into their organization and leverage the full power of the platform.
The platform will now also enable customers to easily select and configure specific ready-made pricing IP – algorithms, data sets, guidance, templates, models and starter kits. Customers will be able to quickly establish connectivity to and distribute IP across their existing instance of Pricefx. Additional platform features include access to foundational services including master data management (MDM), workflow and dashboard capabilities.
Follow Pricefx
Blog: https://www.pricefx.com/site/blog/
Twitter: https://twitter.com/price_fx
LinkedIn: https://www.linkedin.com/company/price-f-x-/
About Pricefx
Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, easy to use, and flexibly adapt to any business need. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, to power pricing Insights, Definitions, and Realization. Their innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to more than 100 customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005046/en/
Contact:
Media Contact: Cathy Summers Summers PR cathy@summers-pr.com +1 (415) 483-0840
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom